Close menu




April 20th, 2020 | 09:43 CEST

Bayer, EXMceuticals, Symrise - investing in the healthcare growth market

  • Healthcare
Photo credits: pixabay.com

The Corona Pandemic brings with it many changes. The influences in the supply chain are affecting the economy to the point of stagnation. The lack of contact for people creates challenges in coping with everyday life. The term 'home office' is used in an inflationary way - and often misused, because the difference between 'home office' and 'working from home' is the noise and stress level around it. On top of this, there are also supply bottlenecks for hygiene products, basic foodstuffs and protective equipment. According to a recent statement by the Federal Minister of Economics, Peter Altmaier (CDU), Germany will need 12 billion masks per year to protect the population. But the well-being of the people also depends on other factors.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA30207T1049 , DE000BAY0017 , DE000SYM9999

Table of contents:


    Early stage opportunity

    The young Canadian company EXMceuticals focuses on the extraction of pure ingredients from the cannabis plant. The company operates as a supplier for the manufacture of products requiring high quality ingredients. EXMceuticals is operationally located in Lisbon, Portugal and is currently planning to set up a production plant there.

    The management around CEO Jonathan Summers sees the European market as the primary sales market. The product world with cannabis as an ingredient is being developed worldwide. The natural active ingredient has already established itself in many areas and the market with pure ingredients is quite lucrative. The EXMceuticals shares enable investors to participate at an early stage with price potential.

    Success story with ingredients

    One of the most renowned companies in the global flavors and ingredients business is Symrise from Germany. In some regions of the world, the population comes into contact with Symrise products 20 to 30 times a day. The flavors and active ingredients are used in more than 30,000 products from over 6,000 customers in more than 100 countries, and their ingredients and flavors ensure natural nutrition.

    Products from Symrise's portfolio can also be found in the cosmetics sector. After a brief period of weakness, the Symrise share price is now back above the level of January 2020.

    Group with diversification

    The shares of the German Bayer Group can also benefit from the period following the Corona Pandemic, as the demand for medical products will continue to grow in the future. It is possible that there will be Bayer's application products that in the future may limit the spread of viral diseases or alleviate their consequences.

    In addition, the acquisition of Monsanto has given the Bayer Group strong roots in the agricultural sector, and the issue of sustainable and healthy nutrition will become an issue that Bayer can address with modern, environmentally friendly products as the population grows around the world. At the moment, the uncertainty surrounding the financial extent of the legal actions for damages in connection with the Monsanto acquisition is creating uncertainties in planning - but the chapter is also finite.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Stefan Feulner on April 29th, 2022 | 11:16 CEST

    BioNTech, NervGen, Sanofi - The rebound is on the way

    • Biotechnology
    • Healthcare

    Uncertainties remain. Admittedly, infection figures are falling in the Corona pandemic and should ensure a quiet summer in this respect. In addition to inflation remaining at a high level, the Ukraine conflict moved to the front news pages. It has caused panic and strong sales on the stock markets in recent weeks. After the DAX marked another interim low at around 13,500 points yesterday, the stock market barometer turned around but is struggling with the psychologically important mark at 14,000 points. Now the quarterly season has begun, which could provide positive impetus. Commerzbank and Deutsche Bank started it off and were quite convincing.

    Read

    Commented by Nico Popp on October 15th, 2021 | 10:10 CEST

    MorphoSys, Sativa Wellness Group, CureVac: Healthcare investments of tomorrow

    • Healthcare

    The healthcare sector is facing a reassessment. For years, especially in Germany, health care has been "fiddled with" - a reform here, a change there, but in basic terms, little has changed in the system in recent years. With the new federal government, things could start to move. Regardless of ideological trench warfare, observers can state, especially under the impression of the pandemic, that innovative treatment methods and preventive care are the most important trends for the future, along with the digitization of the healthcare system. In this context, we present three companies and highlight their opportunities.

    Read

    Commented by Nico Popp on March 17th, 2021 | 07:25 CET

    Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

    • Healthcare

    The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

    Read